Glenmark Life Sciences IPO Details
IPO Date	July 27, 2021 to July 29, 2021
Listing Date	August 6, 2021
Face Value	₹2 per share
Issue Price Band	₹695 to ₹720 per share
Issue Price Final	₹720 per share
Lot Size	20 Shares
Sale Type	Fresh Capital-cum-Offer for Sale
Total Issue Size	2,10,22,222 shares
(aggregating up to ₹1,513.60 Cr)
Fresh Issue	1,47,22,222 shares
(aggregating up to ₹1,060.00 Cr)
Offer for Sale	63,00,000 shares of ₹2
(aggregating up to ₹453.60 Cr)
Issue Type	Bookbuilding IPO
Listing At	BSE, NSE
Share Holding Pre Issue	10,78,04,950 shares
Share Holding Post Issue	12,25,27,172 shares
Glenmark Life Sciences IPO Reservation
Glenmark Life Sciences IPO offers total 2,10,22,222 shares. Out of which 1,05,11,110 (50.00%) allocated to QIB, 42,04,450 (20.00%) allocated to QIB, 31,53,334 (15.00%) allocated to NII, 73,57,778 (35.00%) allocated to RII and 63,06,660 (30.00%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
QIB Shares Offered	1,05,11,110 (50.00%)	NA
NII (HNI) Shares Offered	31,53,334 (15.00%)	NA
Retail Shares Offered	73,57,778 (35.00%)	3,67,888
Total Shares Offered	2,10,22,222 (100.00%)	
Glenmark Life Sciences IPO Anchor Investors Details
Glenmark Life Sciences IPO raises ₹454.08 crore from anchor investors. Glenmark Life Sciences IPO Anchor bid date is July 26, 2021. Glenmark Life Sciences IPO Anchor Investors list

Bid Date	July 26, 2021
Shares Offered	63,06,660
Anchor Portion Size (In Cr.)	454.08
Anchor lock-in period end date for 50% shares (30 Days)	September 2, 2021
Anchor lock-in period end date for remaining shares (90 Days)	November 1, 2021
Glenmark Life Sciences IPO Timeline (Tentative Schedule)
Glenmark Life Sciences IPO opens on July 27, 2021, and closes on July 29, 2021.

IPO Open Date	Tue, Jul 27, 2021
IPO Close Date	Thu, Jul 29, 2021
Tentative Allotment	Tue, Aug 3, 2021
Initiation of Refunds	Wed, Aug 4, 2021
Credit of Shares to Demat	Thu, Aug 5, 2021
Tentative Listing Date	Fri, Aug 6, 2021
Cut-off time for UPI mandate confirmation	5 PM on Thu, Jul 29, 2021
Glenmark Life Sciences IPO Lot Size
Investors can bid for a minimum of 20 shares and in multiples thereof.  The following table depicts the minimum and maximum investment by Individual Investors (Retail) and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (Min)	1	20	₹14,400
Retail (Max)	13	260	₹1,87,200
S-HNI (Min)	14	280	₹2,01,600
S-HNI (Max)	69	1,380	₹9,93,600
B-HNI (Min)	70	1,400	₹10,08,000
Glenmark Life Sciences IPO Promoter Holding
Glenmark Pharmaceuticals Limited is the promoter of the company.
Promoter Holding Pre Issue	100%
Promoter Holding Post Issue	82.84%
Note : The value will be calculated using Equity Dilution = Share Holding Pre Issue - Share Holding Post Issue

About Glenmark Life Sciences Ltd.
Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Competitive strengths

Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
Export products in Europe, Latin America, North America, Japan, and the rest of the world.
Strong relationship with leading global generic companies.
Proven track record of strong financial performance.
High-quality product manufacturing with R&D infrastructure.
Company Financials
Summary of financial Information (Restated Consolidated)
Particulars	For the year/period ended (₹ in million)
31-Mar-21	31-Mar-20	31-Mar-19
Total Assets	19,970.75	17,256.04	14,753.95
Total Revenue	18,859.76	15,493.03	8,868.65
Profit After Tax	3,515.81	3,130.98	1,955.92
Objects of the Issue (Glenmark Life Sciences IPO Objectives)
The Company Glenmark Life Sciences IPO proposes to utilise the Net Proceeds from the Issue towards the following objects:

S.No.	Objects of the Issue	Expected Amount (₹ in crores)
1	Payment of outstanding purchase consideration to the Promoter for thespin-off of the API business from the Promoter into our Companypursuant to the Business Purchase Agreementdated October 9, 2018	800.00
2	Funding the capital expenditure requirements	152.76
3	General corporate purposes	57.68
Glenmark Life Sciences IPO Review
[Dilip Davda]  Though this is a second public issue from Glenmark group after nearly two decades, it is encasing on the fancy of pharma segment amidst pandemic and hence the issue is fully priced discounting all near term positives. Considering the group's credentials and ongoing grey market activities the IPO may evoke a good response. Cash surplus investors may consider investing in this offer with a long term perspective. Read detail review...

Glenmark Life Sciences IPO Subscription Status (Bidding Detail)
The Glenmark Life Sciences IPO is subscribed 44.17 times on July 29, 2021 5:01:00 PM (Day 3). The public issue subscribed 14.63 times in the retail category, 36.97 times in the QIB category, and 122.54 times in the NII category. Check Day by Day Subscription Details (Live Status)

Category	Subscription (times)	Shares Offered	Shares bid for
QIB	36.97	42,42,379	15,68,29,300
NII	122.54	32,32,770	39,61,29,640
Retail	14.63	75,43,130	11,03,65,220
Total	44.17	1,50,18,279	66,33,24,160
Glenmark Life Sciences IPO Prospectus
  ›  Glenmark Life Sciences IPO DRHP
  ›  Glenmark Life Sciences IPO RHP
  ›  Anchor Investors in Glenmark Life Sciences IPO
  ›  Glenmark Life Sciences IPO Final Prospectus
Glenmark Life Sciences IPO Listing Details
Listing Date	August 6, 2021
BSE Script Code	543322
NSE Symbol	ALIVUS
ISIN	INE03Q201024
Final Issue Price	₹720 per share
BSE Listing Group	B (Rolling)
Pre-Open Session - NSEPre-Open Session - BSE

Listing Day Trading Information
Price Details	NSE SME	NSE SME
Final Issue Price	₹720.00	₹720.00
Open	₹751.10	₹750.00
Low	₹737.35	₹738.00
High	₹799.95	₹799.00
Last Trade	₹748.20	₹748.50